Literature DB >> 21925812

Neonatal drug development.

Mark A Turner1.   

Abstract

Drug development is crucial to improving the care given to neonates through new and existing medicines. Pressure from regulatory agencies has improved the way in which pharmaceutical companies work with neonates. This provides new opportunities for the neonatal community. This paper describes the issues that arise during the development of new drugs and considers how the contemporary approach to new drugs can inform research on existing drugs.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925812     DOI: 10.1016/j.earlhumdev.2011.08.014

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  9 in total

1.  Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology.

Authors:  Karel Allegaert
Journal:  World J Clin Pediatr       Date:  2012-08-08

2.  Pharmacological options for BPD prevention: steps for better clinical trial design.

Authors:  R M Viscardi
Journal:  J Perinatol       Date:  2014-09       Impact factor: 2.521

3.  Neonates need tailored drug formulations.

Authors:  Karel Allegaert
Journal:  World J Clin Pediatr       Date:  2013-02-08

4.  The International Neonatal Consortium: collaborating to advance regulatory science for neonates.

Authors:  Mark A Turner; Jonathan M Davis; Susan McCune; Ralph Bax; Ronald J Portman; Lynn D Hudson
Journal:  Pediatr Res       Date:  2016-06-08       Impact factor: 3.756

Review 5.  Educational paper: do we need neonatal clinical pharmacologists?

Authors:  Karel Allegaert; Jean Paul Langhendries; John N van den Anker
Journal:  Eur J Pediatr       Date:  2012-05-16       Impact factor: 3.183

6.  Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates.

Authors:  Georgi Nellis; Tuuli Metsvaht; Heili Varendi; Jana Lass; Jennifer Duncan; Anthony J Nunn; Mark A Turner; Irja Lutsar
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

7.  Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered.

Authors:  Kristine Svinning Valeur; Helle Holst; Karel Allegaert
Journal:  Pharmaceut Med       Date:  2018-08-10

8.  Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial).

Authors:  Serife Kurul; H Rob Taal; Robert B Flint; Jan Mazela; Irwin K M Reiss; Karel Allegaert; Sinno H P Simons
Journal:  BMC Pediatr       Date:  2021-11-18       Impact factor: 2.125

Review 9.  Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy.

Authors:  Brandon J Dixon; Cesar Reis; Wing Mann Ho; Jiping Tang; John H Zhang
Journal:  Int J Mol Sci       Date:  2015-09-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.